Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: defnition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
Feuerstein JD, Nguyen GC, Kupfer SS, et al.; American Gastro-enterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in infammatory bowel disease. Gastroenterology. 2017;153:827-834.
Vande Casteele N, Herfarth H, Katz J, et al. American Gastro-enterological Association Institute technical review on the role of therapeutic drug monitoring in the management of infammatory bowel diseases. Gastroenterology. 2017;153:835-857.e6.
Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with infammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655-1668.e3.
Liefferinckx C, Minsart C, Toubeau J F, et al. Infiximab trough levels at induction to predict treatment failure during maintenance. Infamm Bowel Dis. 2017;23:1371-1381.
Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infiximab predict safety and success of reinitiation of infiximab therapy. Clin Gastroenterol Hepatol. 2014;12:1474-1481.e2.
Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infiximab antibody levels for prediction of primary nonresponse to infiximab therapy. Aliment Pharmacol Ther. 2018;47:212-218.
Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2020;14:542-556.
Vande Casteele N, Baert F, Bian S, et al. Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn's disease: a prospective multicentre study. J Crohns Colitis. 2019;13:1248-1256.
Ungar B, Engel T, Yablecovitch D, et al. Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC Study. Am J Gastroenterol. 2018;113:890-898.
Ward MG, Thwaites PA, Beswick L, et al. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther. 2017;45:1135-1145.
Brandse J F, Mathôt RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infiximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251-258.e1.
Van Stappen T, Vande Casteele N, Van Assche G, et al. Clinical relevance of detecting anti-infiximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2018;67:818-826.
Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
Topol EJ. High-performance medicine: the convergence of human and artifcial intelligence. Nat Med. 2019;25:44-56.
Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Stat. 2001;29:1189-1232.
Breiman L. Random forests. Mach Learn. 2001;45:5-32.
Toubeau J, Bottieau J, Vallée F, et al. Deep learning-based multivar-iate probabilistic forecasting for short-term scheduling in power markets. IEEE Trans Power Syst. 2019;34:1203-1215.
Rodríguez JD, Pérez A, Lozano JA. Sensitivity analysis of kappa-fold cross validation in prediction error estimation. IEEE Trans Pattern Anal Mach Intell. 2010;32:569-575.
Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300.
Petitcollin A, Bensalem A, Verdier MC, et al. Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet. 2020;59:37-49.
Kennedy NA, Heap GA, Green HD, et al.; UK Infammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4:341-353.
Gisbert J P, Chaparro M. Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with infammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14:694-709.
Click B, Anderson AM, Koutroubakis IE, et al. Peripheral eosino-philia in patients with infammatory bowel disease defnes an aggressive disease phenotype. Am J Gastroenterol. 2017;112:1849-1858.
Prathapan KM, Ramos Rivers C, Anderson A, et al. Peripheral blood eosinophilia and long-term severity in pediatric-onset infammatory bowel disease. Infamm Bowel Dis. 2020;26: 1890-1900.
Morgenstern S, Brook E, Rinawi F, et al. Tissue and peripheral eo-sinophilia as predictors for disease outcome in children with ulcer-ative colitis. Dig Liver Dis. 2017;49:170-174.
Kim EM, Randall C, Betancourt R, et al. Mucosal eosinophilia is an independent predictor of vedolizumab efficacy in inflammatory bowel diseases. Inflamm Bowel Dis. 2020;26:1232-1238.
Casteele NV, Jairath V, Jeyarajah J, et al. Development and validation of a clinical decision support tool that incorporates pharmaco-kinetic data to predict endoscopic healing in patients treated with infiximab. Clin Gastroenterol Hepatol. Published online May 4, 2020. doi: 10.1016/j.cgh.2020.04.078.
